retatrutide safety More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Unapproved weight-loss drug "reta" sold

The glucagon receptor activation in Retatrutide may add some additional GI burden in certain subjects, though trial data did not show statistically significant differences vs Tirzepatide at equivalent weight-loss-adjusted doses

The FDA Drug Shortages database has listed semaglutide and tirzepatide products at various times, reflecting manufacturing challenges in meeting unprecedented demand

When patients combine GLP-1 agonist medications with a healthy lifestyle that includes regular exercise and a nutritious diet, they can expect to lose about one pound per week steadily

We keep what is working, and we improve what is not, because significant weight loss is usually built over several months, not just the first 30 days

The researchers note that people previously treated with tirzepatide generally lost more total weight initially, which may partly explain the larger rebound

If you decide to try berberine: Choose third-party tested products (USP, NSF, or equivalent)